{"entity": "publication", "iuid": "97cfc70eeb5a4b8aae6acfdb08f771af", "timestamp": "2026-10-01T11:57:35.860Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/97cfc70eeb5a4b8aae6acfdb08f771af.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/97cfc70eeb5a4b8aae6acfdb08f771af"}}, "title": "CAR T cell therapy for central nervous system solid tumors: current progress and future directions.", "authors": [{"family": "Kaminskiy", "given": "Yaroslav", "initials": "Y"}, {"family": "Degtyarev", "given": "Vitaly", "initials": "V"}, {"family": "Stepanov", "given": "Alexey", "initials": "A"}, {"family": "Maschan", "given": "Michael", "initials": "M"}], "type": "journal article", "published": "2025-08-15", "journal": {"title": "Front Immunol", "issn": "1664-3224", "volume": "16", "pages": "1600403", "issn-l": "1664-3224"}, "abstract": "Central nervous system (CNS) tumors are the second most common type of cancer in children and remain the leading cause of mortality in pediatric oncology. For patients with high-risk CNS tumors, standard treatments often prove ineffective, with survival rates being less than 10%. Hence, there is an urgent need to develop alternative treatment strategies for this patient population. Globally, numerous clinical trials are actively investigating a range of novel therapeutic approaches, from pharmacological and immunological therapies to physical modalities targeting the tumor. Among these emerging therapies, CAR T cell therapy has shown great promise, with the first objective clinical responses already reported. This review aims to evaluate the current landscape of CAR T cell therapy for pediatric CNS tumors, focusing on clinical efficacy, toxicity profiles of systemic and locoregional delivery, antigen heterogeneity, and key challenges in clinical implementation. We provide a comprehensive analysis of reported clinical trials, including not only CAR T cell studies but also investigations involving tumor-infiltrating lymphocytes (TILs), NK and lymphokine-activated killer (LAK) cells, offering a broader perspective on immunotherapeutic approaches for CNS malignancies.", "doi": "10.3389/fimmu.2025.1600403", "pmid": "40895575", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12394536"}], "notes": [], "created": "2026-10-01T08:28:35.150Z", "modified": "2026-10-01T08:28:35.174Z"}